Send to:

Choose Destination
See comment in PubMed Commons below
J Alzheimers Dis. 2010;21(3):903-14. doi: 10.3233/JAD-2010-100408.

A copper-lowering strategy attenuates amyloid pathology in a transgenic mouse model of Alzheimer's disease.

Author information

  • 1Portland Veterans Affairs Medical Center, P3 R&D, Portland, OR, USA.


There is increasing evidence for the crucial role of metals in the pathology of Alzheimer's disease. Both the aggregation and neurotoxicity of amyloid-β are dependent on the presence of copper. This study investigated the ability of the copper-complexing drug tetrathiomolybdate to reduce amyloid-β pathology and spatial memory impairment in both a prevention and a treatment paradigm in the Tg2576 mouse model of Alzheimer's disease. Tetrathiomolybdate treatment lowered brain copper and reduced amyloid-β levels in the prevention paradigm, but not in the treatment paradigm. Our data suggests that controlled lowering of systemic copper may achieve anti-amyloid effects if initiated early in the disease process.

[PubMed - indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for IOS Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk